Novo Nordisk on Friday presented a suite of late-stage clinical data at the American Diabetes Association's 86th Scientific Sessions, spotlighting cardiovascular outcomes for oral semaglutide and expanding evidence for its GLP-1 portfolio across obesity, type 2 diabetes, and metabolic disease. The presentations, previewed by the company on Thursday, drew significant attention from endocrinologists and cardiologists gathered at the conference, which is among the most closely watched annual events in diabetes medicine.
Central to Friday's disclosures were findings from trials examining once-daily oral semaglutide at higher doses, with data suggesting meaningful reductions in major adverse cardiovascular events among patients with established heart disease and type 2 diabetes. Novo Nordisk executives described the results as reinforcing the company's case for broader prescribing guidelines and potential label expansions in both the United States and European markets.
The ADA sessions also featured data on CagriSema, Novo Nordisk's investigational combination of cagrilintide and semaglutide, which has been positioned as a potential next-generation obesity therapy capable of delivering greater weight loss than semaglutide alone. Analysts tracking the company have pointed to these readouts as critical to defending Novo Nordisk's market position against Eli Lilly's tirzepatide franchise, which has gained considerable ground over the past year.
Beyond the headline obesity and cardiovascular data, Novo Nordisk presented findings related to semaglutide's effects on kidney disease progression and non-alcoholic steatohepatitis, reflecting the company's strategy of broadening the drug's approved indications. Patient advocacy groups attending the conference welcomed the cardiovascular and renal data, while independently noting that access and affordability remain significant barriers for many patients in lower-income settings and among the uninsured in the United States.
Shares of Novo Nordisk moved modestly in early European trading ahead of the presentations, with investors closely monitoring whether the data would restore confidence following a period of competitive pressure from Lilly. Healthcare analysts from Morgan Stanley and JPMorgan were expected to publish updated notes on the company's pipeline valuation by end of day Friday, with consensus sentiment leaning cautiously positive pending the full dataset release.